Where All This Came From

National Institute on Drug Abuse, National Household Survey on Drug Abuse: Population Estimates - 1994 (Department of Health and Human Services, Public Health Service, Bethesda, MD, 1995).

ACLU National Survey of Voters' Opinions on the Use and Legalization of Marijuana for Medical Purposes (March 31-April 5, 1995).

National Commission on Marijuana and Drug Abuse, Marijuana, A Signal of Misunderstanding (New York: The New American Library, Inc., 1972).

Single E.W., The Impact of Marijuana Decriminalization: An Update (Journal of Public Health Policy, Vol. 10, P. 456-66, 1989);

Johnston L.,O'Malley P., and Bachman J., Marijuana Decriminalization: The Impact on Youth, 1975-80 (Monitoring the Future, Occasional Paper Series #13);

Maloff D., A Review of the Effects of the Decriminalization of Marijuana,(Contemporary Drug Problems, Fall 1981).

Grinspoon L., Bakalar J., Marihuana, the Forbidden Medicine (Yale University Press, New Haven, Conn. 1993);

Grinspoon L., Bakalar J., Marihuana as a Medicine: A Plea for Reconsideration (JAMA, June 21, 1995, Vol. 273, No. 23);

The American Public Health Association, Resolution 9513, Access to Therapeutic Marijuana/Cannabis (APHA Public Policy Statements, Washington, DC, November 1995);

Federation of American Scientists, Medical Use of Whole Cannabis (Washington, DC, 1994);

National Task Force on Cannabis, The Health and Psychological Consequences of Cannabis Use (Australian Government Publishing Service, Canberra, Australia, 19 -need year);

Institute of Medicine, National Academy of Sciences, Marijuana and Health, A Report of a Study by a Committee of the Institute of Medicine (National Academy Press, Washington, DC, 1982).

The American Public Health Association, Resolution 9513, Access to Therapeutic Marijuana/Cannabis (APHA Public Policy Statements, Washington, DC, 1995).

Federation of American Scientists, Medical Use of Whole Cannabis (Washington, DC, 1994).

Goldberg C., Marijuana Club Helps Those In Pain (N.Y. Times, February 25, 1996).

In the Matter of Marijuana Rescheduling Petition, Docket 86-22, Opinion, Recommended Ruling, Finding of Fact, Conclusions of Law, and Decision of Administrative Law Judge, September 6, 1988 (Drug Enforcement Agency, Washington, DC, 1988).

Alt States of Consciousness Ed. by Charles Tart p334 Anchor Paperback

Kv'alseth, T.O., "Effects of Marijuana on Human Reaction Time and Motor Control," Perceptual and Motor Skills 45:935-39 (1977);

Hansteen, R.W. et al, "Effects of Cannabis and Alcohol on Automobile Driving and Psychomotor Tracking," Annals of New York Academy of Sciences 282:240-56 (1976);

Moskowitz, H. et al, "Marijuana: Effects on Simulated Driving Performance," Accident Analysis and Prevention 8:45-50 (1976);

Moskowitz, H. et al, "Visual Search Behavior While Viewing Driving Scenes Under the Influence of Alcohol and Marijuana" Human Factors 18:417-31 (1976). (back)

Stein, A.C. et al, A Simulator Study of the Combined Effects of Alcohol and Marijuana on Driving Behavior-Phase II, Washington, DC: U.S. Department of Transportation (1983). (back)

Robbe, H. and O'Hanlon, J., Marijuana and Actual Driving Performance, Washington, DC: Department of Transportation (1993). (back)

Carter, W.E. (ed), Cannabis in Costa Rica: A Study of Chronic Marijuana Use, Philadelphia: Institute for Study of Human Issues (1980);

Rubin, V. and Comitas, L., Ganja in Jamaica, The Hague: Mouton (1975);

Stefanis, C. et al, Hashish: Studies of Long Term Use, New York: Raven Press (1977).

Herndon, G.M., 'Hemp in Colonial Virginia', 1963; 'The Chesapeake Colonies', 1954; L.A.Times, Aug 12, 1981; et al

Michael R. Sonnenreich, 'Discussion of the Final Report of the National Commission on Marijuana and Drug Abuse, in 'Villanova Law Review', 18:817-827 (May), 1973, p818

Beaconsfield, D., Ginsburg, J., and Rainsbury, R. (1973). Therapeutic potential of marihuana. New Eng. J. Medicine 289, 1315.

Therapeutic Aspects. 1974. Marijuana and Health, Fourth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 134-143.

Therapeutic Aspects. 1975. Marijuana and Health, Fifth Annual Report to the U.S. Congress, Nat'l Institute on Drug Abuse, 117-132.

Bhargave, H. (1978). Potential therapeutic application of naturally occurring and synthetic cannabinoids. Gen. Pharmac., 9, 195-213.

Ungerleider, J. (1979). Marijuana as a good medicine: Its uses against disease. Lecture delivered to UCLA Center for the Health Sciences, August 21, 1979.

Zinberg, N. (1979). On cannabis and health. J. Psychedelic Drugs, 11, 135-144.

AMA Council on Scientific Affairs. (1980). Marihuana reexamined: Pulmonary risks and therapeutic potentials. Conn. Medicine, 44, 521-523. Cohen, S. (1980).

Therapeutic aspects. Nat'l Inst. Drug Abuse. Res. Mono. Ser., No. 31, 199-216.

Council on Scientific Affairs. (1981). Marijuana: Its health hazards and therapeutic potentials. JAMA, 246, 1823-1827.

DuQuesne, J. (1981). Cannabis and the Rule of Law. Lancet, Sept. 12, 1981, 581.

Rose, M. (1981). Cannabis and the rule of law. Lancet, July 18, 1981.

Therapeutic potential and medical uses of marijuana. (1982). In Marijuana and Health, Inst. of Medicine, 139-155.

Schurr, A. (1985). Marijuana: Much ado about THC. Comp. Biochem. Physiol., 80 C, 1-7.

Ungerleider, J. and Andrysiak, T. (1985). Therapeutic issues of marijuana and THC., Int'l J. Addictions, 20, 691-699.

Grinspoon, L. and Bakalar, J., (1995). Marihuana as Medicine, A Plea for Reconsideration, JAMA, 273: 1875-1876.

Hollister, L (1970) Hunger and appetite after single doses of marihuana, alcohol and dextroamphetamine. Clin. Pharmacol. and Therapeutics, 12, 44-49.

Sallan, S.E., Zinberg, N.E., Ferei, E., III, (1975), Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Eng. J.Med., 293, 795-797.

Greenberg, I., Kuehnle, J., Mendelson,J.H. and Bernstein, J.G. 1976. Effects of marihuana use on body weight and caloric intake in human. Journal of Psychopharmacology (Berlin) 49: 79-84.

Harris, L. (1976). Analgesic and antitumor potential of the cannabinoids. In Therapeutic Potential of Marijuana. (Cohen and Stillman, eds., 299-309.

Harris, L. Munson, A. and Carchman, R. (1976). Antitumor properties of cannabinoids. In The Pharmacology of Marihuana (Braude and Szara, eds.), 749-762.

Chang, A. et al. (1979). Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. Annals of Internal Medicine, 91, 819-824.

Sallan, S.E., Cronin, C. Zelen, M., Zinberg, N.E. (1980). Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N. Engl. J. Med., 302: 135-8.

California State Reports, Therapeutic Cannabis Program, Annual Report to the Governor and Legislature, California Research Advisory Panel (1980-1986).

Bateman, D.C., Rawlins, M. (1982). Therapeutic potential of cannabinoids. Br. Med. J., 284, 1211-1212.

Cannabinoids for nausea, (1981). Lancet, Jan. 31, 1981, 255-256.

Frytek, S., Moertel, C.G., (1981), Management of nausea and vomiting in the cancer patient, JAMA, 245, 394-396.

Neidhart, J., Gagen, M., Wilson, H. and Young, D. (1981). Comparative trial of the antiemetic effects of THC and haloperidol. J. Clin. Pharmacol., 21, 385-425.

Michigan Department of Public Health Marijuana Therapeutic Research Project,

Trial A 1980-81," Department of Social Oncology, Evaluation Unit, Michigan Cancer Foundation (March 18, 1982).

Ungerleider, J., Andrysiak, T., Fairbanks, L., Goodnight, J., Sama, G. and Jamison, K. (1982). Cancer chemotherapy and marijuana.

Ungerleider, J., Andrysiak, T., Fairbanks, L., Goodnight, J., Sama, G. and Jamison, K. (1982). Cannabis and cancer chemotherapy: A comparison of oral delta-9-THC and prochlorperazine. Cancer, 50, 636-645.

Sensky, T., Baldwin, A., and Pettingale, K. (1983). Cannabinoids as antiemetics. Br. Med. J. , 286, 802.

Kutner, Michael H., Evaluation of the Use of Both Marijuana and THC in Cancer Patients for the Relief of Nausea and Vomiting Associated with Cancer Chemotherapy After Failure of Conventional Anti-Emetic Therapy: Efficacy and Toxicity" as prepared for the Composite State Board of Medical Examiners, Georgia Department of Health, by physicians and researchers at Emory University, Atlanta, (January 20, 1983).

Annual Report: Evaluation of Marijuana and Tetrahydrocannabinol in the Treatment of Nausea and/or Vomiting Associated with Cancer Therapy Unresponsive to Conventional Anti-Emetic Therapy: Efficacy and Toxicity," Board of Pharmacy, State of Tennessee, July 1983.

The Lynn Pierson Therapeutic Research Program," the Behavioral Health Sciences Division, Health and Environment Department, March 1983 and 1984.

Foltin, R.W., Brady, J.V. and Fischman, M.W. 1986. Behavioral analysis of marijuana effects on food intake in humans. Pharmacology, Biochemistry and Behavior. 25: 577-582.

Foltin, R.W. et al., 1988 Effects of Smoked Marijuana on Food Intake and Body Weight of Humans Living in a Residential Laboratory," Appetite 11:1-14

Vinciguerra, V., Moore, T., Brennab, E., Inhalation marijuana as an antiemetic for cancer chemotherapy, (Oct. 1988) N.Y. State J. Medicine, 525-527.

T.F. Plasse, R.W. Gorter, S.H. Krasnow, et al., 1991. Recent clinical experience with dronabinol. Pharmacology, Bichemistry and Behavior 40: 695-700.

Doblin, R., Kleiman, M., Marijuana as antiemetic medicine: A survey of oncologists' experiences and attitudes, (1991), J. Clin. Oncology, 9:7, 1314-1319.

Abrams, D. 1995, Marijuana, the AIDS Wasting Syndrome, and the U.S. Government (Response to Letter) New England Journal of Medicine, Vol. 333 (10): 670-671.

Grinspoon, L, J, and Doblin, R. 1995. Marijuana, the AIDS Wasting Syndrome, and the U.S. Government (Letter to ed.) New England Journal of Medicine, Vol. 333(10): 670-671.

Wesner, B. 1996. The Medical Marijuana Issue Among PWAs: Reports of Therapeutic Use and Attitudes Toward Legal Reform. Drug Research Unit, Social Science Research Institute, University of Hawaii at Manoa.

Hepler, R. and Frank, I., (1971). Marijuana smoking and intraocular pressure. JAMA, 217, 1932.

Hepler, R., Frank, I. and Ungerleider, J. (1972). Pupillary constriction after marijuana smoking. Am. J. Ophthalmol., 74, 1185-1190.

Shapiro, D. (1974). The ocular manifestations of the cannabinoids. Opthalmologica, 168, 366-369.

Hepler, R. and Petrus, R. (1976). Experiences with administration of marijuana to glaucoma. In The Therapeutic Potential of Marijuana. (Cohen and Stillman, eds.), 63-75.

Perez-Reyes, M., Wagner, D., Wall, M. and Davis, K. (1976). Intravenous administration of cannabinoids and intraocular pressure. In The Pharmacology of Marihuana (Braude and Szara, eds.), 829-832.

Goldberg, I., Kass, M. and Becker, B. (1978-1979). Marijuana as a treatment for glaucoma. Sightsaving Review, Winter issue, 147-154.

Crawford, W., and Merritt, J. (1979). Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int'l J. Clin. Pharmacol. and Biopharm. 17, 191-196.

Merritt, J., Crawford, W., Alexander, P., Anduze, A. and Gelbart, S. (1980). Effect of marihuana on intraocular and blood pressure in glaucoma.Ophthalmology, 87, 222-228.

Merritt, J., McKinnon, S., Armstrong, J., Hatem, G. and Reid, L. (1980). Oral delta-9-tetrahydrocannabinol in heterogenous glaucomas. Annals of Ophthalmology, 12, No. 8.

Zimmerman, T. (1980). Efficacy in glaucoma treatment-the potential of marijuana. Annals of Ophthalmology, 449-450.

Green, L., (1984) Marijuana effects on intraocular pressure, Applied, Pharmacology in the Medical Treatment of Glaucomas, (S.M. Drance, ed.), 507-526.

Merritt, J., et al. (1981). Effects of topical delta-9-tetrahydrocannabinol on intraocular pressure in dogs. Glaucoma, Jan./Feb., 13-16.

Merritt, J., Perry, D., Russell, D. and Jones, B. (1981). Topical delta-9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J. Clin. Pharmacol., 21, 467S-471S.

Merritt, J., Olsen J., Armstrong, J. and McKinnon, S. (1981). Topical delta-9-tetrahydrocannabinol in hypertensive glaucomas. J. Phar. Pharmacol., 33, 40-41.

Merritt, J. (1982). Glaucoma, hypertension, and marijuana. J. Nat'l Med. Ass'n., 74, 715-716.

Merritt, J., Cook, C. and Davis, K. (1982). Orthostatic hypotension after delta-9- tetrahydrocannabinol marihuana inhalation. Ophthalmic Res., 14, 124-128.

Merritt, J. et al. (1982). Topical delta-8-tetrahydrocannabinol as a potential glaucoma agent. Glaucoma, 4 253-255.

Merritt, J. (1984). Outpatient cannabinoid therapy for heterogenous glaucomas: Guidelines for institution and maintenance of therapy. Marijuana 84: Proceedings of the Oxford Symposium on Cannabis, 681-683.

Merritt, J., Shrewsbury, R., Locklear F., Demby, K. and Wittle, G. (1986), Effects of delta-9-tetrahydrocannabinol and vehicle constituents on intraocular pressure in normotensive dogs. Research Communication in Substances of Abuse, 7, 29-35.

Carlini, E., Leite, J., Tannhauser, M. and Berardi, A. (1973). Cannabidiol and cannabis sativa extract protect mice and rats against convulsive agents. J. Pharm. Pharmac., 25, 664-665.

Karler, R., Cely, W., and Turkanis, S. (1973). The anticonvulsant activity of cannabidiol and cannabinol. Life Sciences, 13, 1527-1531.

Dunn, M. and Davis, R., (1974). The perceived effects of marijuana on spinal cord injured males, Paraplegia, 12, 175.

Turkanis, S., Cely, W., Olsen, D. and Karler, R. (1974). Anticonvulsant properties of cannabinol. Res. Comm. Chem. Path. Pharmacol., 8, 231-246.

Consroe, P., Wood, G., and Buchsbaum, H. (1975). Anticonvulsant nature of marijuana smoking. JAMA, 234, 306-307.

Karler, R. and Turkanis, S. 1976. The antiepileptic potential of the cannabinoids. In The Therapeutic Potential of Marijuana, (Cohen and Stillman, eds.), 383-396.

Feeney, D.M., Marihuana and epilepsy: paradoxical anticonvulsant and convulsant effects, Marijuana Biological Effects: Analysis, Metabolism, Cellular Responses, Reproduction and the Brain, (Nahas, GG., Paxton, M., Bruade, J.C., Hardillier, and Harvey, D.J. eds.) Pergamon Press, Oxford, England, 643-657.

Petro, D., (1980), Marihuana as a therapeutic agent for muscle spasm of spasticity, Psychosomatics, 21: 81, 85.

Cunha, J., et al. (1980). Chronic administration of cannabidiol to health volunteers and epileptic patients. Pharmacology, 21, 175-185.

Petro, D., Ellenberger, C., Jr., (1981). Treatment of human spasticity with delta-9- tetrahydrocannabinol, J. Clin. Pharmacol., 21:413S-416S.

Clifford, D.B.. 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology. 13: 669-671.

Sandyk, R., Consroe, P., Stern, L., Snider, S., (1986). Effects of cannabidiol in Huntington's Disease, Neurology, 36:331.

Hanigan, W.C., Destree,R. and Truong, X.T., (Feb., 1986), The effect of delta-9- tetrahydrocannabinol on human spasticity, Clin. Pharmacol. Ther., 198. Truong, X.T.,

Hanigan, W.C., (Feb. 1986). Effect of delta-9-tetrahydrocannabinol on EMG measurements in human spasticity. Clin. Pharmacol. Ther., 232.

Cannabis, (1986) Therapeutic Claims in Multiple Sclerosis, Int'l Federation of Multiple Sclerosis Societies, 226.

Ames, F. and Cridland, S. (1986). Anticonvulsant effects of cannabidiol. S. Afr. Med. J., 69, 14.

Ungerleider, T. 1987.Delta 9 THC in treatment of spasticity associated with marijuana. Advances in Alcohol and Substance Abuse, 7: 39-51.

Meinck, H.M., Schonle, P.W., Conrad, B. 1989. Effect of Cannabinoids on Spasticity and Ataxia in multiple sclerosis. Journal of Neurology 236: 120-122.

Maurer, M., Henn, V., Dittrich A., Hoffamn, A., 1990. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. European Archives of Psychiatry and Clinical Neuroscience 240: 1-4.

Back to Start